GRIFOLS S A/S (NASDAQ:GRFS) Rating Increased to Buy at Banco Sabadell

Share on StockTwits

Banco Sabadell upgraded shares of GRIFOLS S A/S (NASDAQ:GRFS) from a sell rating to a buy rating in a report released on Monday, The Fly reports.

Several other analysts have also weighed in on GRFS. Santander raised GRIFOLS S A/S from a hold rating to a buy rating in a research note on Monday, October 28th. Zacks Investment Research lowered GRIFOLS S A/S from a hold rating to a sell rating in a research note on Friday, December 6th. Berenberg Bank raised GRIFOLS S A/S to a buy rating in a research note on Wednesday, October 30th. ValuEngine raised GRIFOLS S A/S from a sell rating to a hold rating in a research note on Wednesday, October 2nd. Finally, BidaskClub raised GRIFOLS S A/S from a sell rating to a hold rating in a research note on Wednesday, December 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $20.75.

NASDAQ:GRFS opened at $22.73 on Monday. The stock’s 50-day simple moving average is $22.06 and its 200 day simple moving average is $21.05. The firm has a market capitalization of $15.59 billion, a PE ratio of 19.43, a price-to-earnings-growth ratio of 1.41 and a beta of 1.06. The company has a quick ratio of 0.96, a current ratio of 2.62 and a debt-to-equity ratio of 1.30. GRIFOLS S A/S has a twelve month low of $17.42 and a twelve month high of $23.60.

GRIFOLS S A/S (NASDAQ:GRFS) last released its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.03). The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.39 billion. GRIFOLS S A/S had a net margin of 11.12% and a return on equity of 13.58%. On average, analysts anticipate that GRIFOLS S A/S will post 1.16 EPS for the current fiscal year.

The company also recently declared a semi-annual dividend, which was paid on Wednesday, December 11th. Stockholders of record on Tuesday, December 3rd were paid a dividend of $0.169 per share. This represents a dividend yield of 1.3%. This is a positive change from GRIFOLS S A/S’s previous semi-annual dividend of $0.15. The ex-dividend date was Monday, December 2nd. GRIFOLS S A/S’s dividend payout ratio (DPR) is presently 29.06%.

Several institutional investors and hedge funds have recently modified their holdings of GRFS. Aperio Group LLC raised its position in shares of GRIFOLS S A/S by 11.6% during the second quarter. Aperio Group LLC now owns 302,315 shares of the biotechnology company’s stock worth $6,379,000 after acquiring an additional 31,527 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of GRIFOLS S A/S by 11.4% during the second quarter. Janus Henderson Group PLC now owns 1,034,298 shares of the biotechnology company’s stock worth $21,840,000 after acquiring an additional 105,562 shares during the last quarter. Kornitzer Capital Management Inc. KS raised its position in shares of GRIFOLS S A/S by 3.9% during the second quarter. Kornitzer Capital Management Inc. KS now owns 263,500 shares of the biotechnology company’s stock worth $5,560,000 after acquiring an additional 10,000 shares during the last quarter. CIBC Private Wealth Group LLC raised its position in shares of GRIFOLS S A/S by 10.9% during the second quarter. CIBC Private Wealth Group LLC now owns 552,011 shares of the biotechnology company’s stock worth $11,647,000 after acquiring an additional 54,365 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its position in shares of GRIFOLS S A/S by 3.8% during the second quarter. Envestnet Asset Management Inc. now owns 1,090,599 shares of the biotechnology company’s stock worth $23,012,000 after acquiring an additional 39,860 shares during the last quarter. Institutional investors own 18.18% of the company’s stock.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Recommended Story: How dollar cost averaging works

The Fly

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hartford Financial Services Group Inc  Shares Sold by Benin Management CORP
Hartford Financial Services Group Inc Shares Sold by Benin Management CORP
SYSCO Co.  Position Reduced by Benin Management CORP
SYSCO Co. Position Reduced by Benin Management CORP
Benin Management CORP Purchases 1,000 Shares of Merck & Co., Inc.
Benin Management CORP Purchases 1,000 Shares of Merck & Co., Inc.
11,677 Shares in Truist Financial Corporation  Acquired by Benin Management CORP
11,677 Shares in Truist Financial Corporation Acquired by Benin Management CORP
Benin Management CORP Decreases Stock Holdings in Paychex, Inc.
Benin Management CORP Decreases Stock Holdings in Paychex, Inc.
Benin Management CORP Decreases Stock Position in Halliburton
Benin Management CORP Decreases Stock Position in Halliburton


© 2006-2020 Ticker Report